The client
An established pharmaceutical company with a strong immunology portfolio was looking to build consensus and alignment around a forward-looking strategy to maintain their leadership in immunology.
Challenge
A growing number of potential new therapies and technologies can be leveraged in the immunology space, as well as a wide variety of indications driven by shared underlying pathways and processes. The client was interested in defining an immunology strategy by prioritizing the most compelling disorder and technology platform opportunities and building alignment among cross-functional stakeholders to drive the unified strategy for the mid- to long-term.
Approach
We defined and prioritized diseases and technologies of interest, leveraged internal interviews, secondary research, and previous analyses.
Next, we generated primary insights through comprehensive interviews with physicians, patients, and payers for the prioritized opportunities.
We then cemented organizational alignment via a workshop with ~40 cross-functional stakeholders on overall strategy and finalized specific recommendations, a small-group follow up, and the development of an executive level read out.
